Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years

Clinical and Experimental Allergy

Volumn 35, Issue 5, 2005, Pages 560-564

  Di Rienzo, V ^a   Minelli, M ^b   Musarra, A ^c   Sambugaro, R ^d   Pecora, S ^e   Canonica, W G ^f   Passalacqua, Giovanni ^e,f  

^a Clinica Villa Benedetta   (Italy)

^b ASL Lecce   (Italy)

^c National Healthcare System   (Italy)

^d Pediatric Allergy Unit   (Italy)

^e University of Genoa ^*  (Italy)

^f UNIVERSITY OF GENOA   (Italy)

Author keywords

Children; Respiratory allergy; Safety; Side effects; Sublingual immunotherapy

Indexed keywords

IMMUNOMODULATING AGENT;

ABDOMINAL PAIN; ALTERNARIA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; DIARRHEA; DOSE RESPONSE; DRUG SAFETY; EYE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRASS; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MITE; NAUSEA; OLIVE; PARIETARIA; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT ALLERGY; RHINITIS; SUBLINGUAL DRUG ADMINISTRATION; URTICARIA; VOMITING;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ALTERNARIA; ASTHMA; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; PARIETARIA; PRODUCT SURVEILLANCE, POSTMARKETING; PYROGLYPHIDAE; RESPIRATORY HYPERSENSITIVITY; RHINITIS;

EID: 20044393372     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2005.02219.x     Document Type: Article

References (29)

1. Bousquet J, Lockey R, Malling HJ. World Health Organization Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53 (Suppl. 44): 1-42.
2. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinits and its impact on asthma. J Allergy Clin Immunol 2001; 108 (Suppl. 5): S147-334.
3. Canonica GW, Passalacqua G. Non injection routes for immunotherapy. J Allergy Clin Immunol 2003; 111:437-48.
4. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis (Cochrane review). Cochrane Database Syst Rev 2003: CD002893.
5. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in children. Allergy 1999; 54:1110-3.
6. Lombardi C, Gargioni S, Melchiorre A et al. Safety of sublingual immunotherapy in adults: a post marketing surveillance study. Allergy 2001; 56:889-92.
7. Pajno GB, Peroni DG, Vita D, Pietrobelli A, Parmiani S, Boner AL. Safety of Sublingual immunotherapy in children with asthma. Paediatr Drugs 2003; 5:777-81.
8. Khinchi MS, Poulsen LK, Carat F, André C, Hansen AB, Malling H-J. Clinical efficacy of sublingual and subcutaneous birch pollen allergen specific immunotherapy. A randomized placebo controlled, double blind, double dummy study. Allergy 2004; 59:45-53.
9. Andre' C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000; 121:229-34.
10. Grosclaude M, Bouillot P, Alt R et al. Safety of various dosage regimens during induction of sublingual immunotherapy. Int Arch Allergy Immunol 2002; 129:248-53.
11. Passalacqua G, Albano M, Riccio AM et al. Clinical and immunological effects of a rush sublingual immunotherapy to Parietaria species: a double blind placebo controlled trial. J Allergy Clin Immunol 1999; 104:964-8.
12. La Rosa M, Ranno C, Andre' C et al. Double blind placebo controlled evaluation of sublingual swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999; 104: 425-32.
13. Vourdas D, Syrigou E, Potamianou P et al. Double blind placebo controlled evaluation of sublingual immunotherapy with a standardized olive tree pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive tree pollen sensitization. Allergy 1998; 53:662-71.
14. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunological effects of longterm sublingual immunotherapy in asthmatic children sensitized to mite: a double blind study. Allergy 2000; 55:842-9.
15. Caffarelli C, Sensi L, Marcucci F, Cavagni C. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000; 55: 1142-7.
16. Ippoliti F, De Sanctis W, Volterrani A et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14:216-21.
17. Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114:851-9.
18. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-6.
19. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real life: clinical efficacy and more. Allergy 2004; 59:1205-10.
20. Ostergaard PA, Kaad PH, Kristensen T. A prospective study on the safety of immunotherapy in children with severe asthma. Allergy 1986; 41:588-93.
21. Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of sublingual immunotherapy in very young children. Allergy 2005; 60:133.
22. Andre' C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000; 121:229-34.
23. Mosbech H, Dreborg S, Madsenn F et al. High dose grass pollen tablets used for hyposensitization in hay fever patients. A one year double blind placebo controlled study. Allergy 1987; 42:451-5.
24. Passalacqua G, Villa G, Altrinetti V et al. Sublingual swallow or spit? Allergy 2001; 56:578.
25. Sambugaro R, Puccinelli P, Burastero SE, Di Rienzo V. The efficacy of sublingual immunotherapy for respiratory allergy is not affected by different dosage regimens in the induction phase. Allergol Immunopathol (Madr) 2003; 31:329-37.
26. Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003; 33: 1641-7.
27. Purello-D'Ambrosio F, Gangemi S, Isola S et al. Sublingual immunotherapy: a doubleblind, placebo controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy 1999; 54: 968-73.
28. Di Rienzo V, Marcucci F, Puccinelli P et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003; 33:206-10.
29. Bernardis P, Agnoletto M, Puccinelli P, Parmiani S, Pozzan M. Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients. J Invest Allergol Clin Immunol 1996; 6:55-62.